3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Breast
1
Conditions
Breast Neoplasms
8
Polycystic Ovary Syndrome
3
Peripheral Nervous System Diseases
2
Obesity
2
Neoplasms
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Triple Negative Breast Neoplasms
1
Tracheal Diseases
1
TP53 Y220C Mutation
1
Squamous Cell Carcinoma of Head and Neck
1
Smoking
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Pulmonary Disease, Chronic Obstructive
1
Pancreatic Neoplasms
1
Overweight
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Multiple Myeloma
1
Motor Activity
1
Mesothelioma
1
Meningioma
1
Medulloblastoma
1
Interventions
epigallocatechin gallate
2
Ascorbic Acid
2
semaglutide
1
microcrystalline cellulose
1
dapagliflozin
1
cytisine
1
bupropion hydrochloride, naltrexone hydrochoride drug combination
1
XENP 1595
1
Vitamin D
1
Topiramate
1
Tirzepatide
1
Tablets
1
Spirometry
1
Specimen Handling
1
Selenium
1
Saline Solution
1
Resistance Training
1
Reperfusion
1
Qsymia
1
Probiotics
1
Pregabalin
1
Platelet Count
1
Plastic Surgery Procedures
1
Phentermine
1
Omeprazole
1
Naltrexone
1
Losartan
1
Liraglutide
1
Ketorolac
1
Ischemic Preconditioning
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Inflammation
×
Tablets
×
1 year
×
Clear all
NCT06150898
2025-06-13
KePreSt
Jules Bordet Institute
Phase 2
Recruiting
112 enrolled